You are here

Article info

Article menu
Download PDFPDF
Inflammatory bowel disease
Original article
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

Authors

  1. Correspondence to Dr Silvio Danese, Department of Gastroenterology, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan 20089, Italy; sdanese{at}hotmail.com
View Full Text

Citation

Danese S, Rudziński J, Brandt W, et al
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
Gut 2015;64:243-249.

Publication history

  • Received July 8, 2014
  • Revised September 17, 2014
  • Accepted September 18, 2014
  • First published October 10, 2014.
Online issue publication 
April 18, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions